What to know about Roche’s experimental Alzheimer’s treatment; Milestone Pharma’s nasal spray achieves goal of key study

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     STAT+: What to know about Roche's experimental Alzheimer's treatment By Adam Feuerstein and Damian Garde Sebastien Bozon/AFP via Getty Images Interest in the readout on gantenerumab has heightened since drugmakers Eisai and Biogen announced positive results for lecanemab. Read More STAT+: Josh Bilenker's last biotech sold for $8 billion. His next one is cloaked in mystery but loaded with money By Matthew Herper and Allison DeAngelis AP Photo/Ted S. Warren Josh Bilenker sold his last company to Eli Lilly for $8 billion. His next effort, Treeline, has already raised nearly $475 million. Read More Sponsored Insight by AWS MARKETPLACE Collecting and harmonizing real-world data Join this webinar to hear from data leaders at AWS, Qiagen, TriNetX and Prognos, as they discuss how real-world data is integral to ensuring patient health. You'll learn how leveraging insights from real-world data as part of a wider data strategy can help to gain critical patient insights. Register now. STAT+: Milestone Pharma's nasal spray rapidly restores normal heart rhythm, achieving goal of key study By Adam Feuerstein Adobe Results of a study announced on Monday show etripamil to be an effective treatment for paroxysmal supraventricular tachycardia. Read More Monday, October 17, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser